Injection, Subcutaneous

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.

Topline data from an ongoing clinical trial of a higher dose regimen of Spinraza in treatment-naive, symptomatic infants with spinal muscular atrophy showed significantly improved motor function at 6 months.

Evaluation of the efficacy, safety and tolerability of a subcutaneous injection of inclisiran (The Medicines Company).

Children aged 6 to 11 years with severe atopic dermatitis assigned dupilumab and topical corticosteroids significantly improved in measures of overall disease severity, skin clearing, itching and health-related quality of life vs. topical corticosteroids alone in a phase 3 trial.